▶ 調査レポート

非アルコール性脂肪肝疾患治療薬の世界市場（～2026年）
• 英文タイトル：Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size, Status and Forecast 2020-2026

QYResearchが調査・発行した産業分析レポートです。非アルコール性脂肪肝疾患治療薬の世界市場（～2026年） / Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size, Status and Forecast 2020-2026 / MRC2-11QY03994資料のイメージです。• レポートコード：MRC2-11QY03994
• 出版社/出版日：QYResearch / 2020年11月20日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア
• 販売価格（消費税別）
  Single User￥577,200 (USD3,900)▷ お問い合わせ
  Multi User￥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License￥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
当調査資料は非アルコール性脂肪肝疾患治療薬のグローバル市場について調査・分析したレポートです。種類別（経口、非経口）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別非アルコール性脂肪肝疾患治療薬の競争状況、市場シェア
・世界の非アルコール性脂肪肝疾患治療薬市場：種類別市場規模 2015年-2020年（経口、非経口）
・世界の非アルコール性脂肪肝疾患治療薬市場：種類別市場規模予測 2021年-2026年（経口、非経口）
・世界の非アルコール性脂肪肝疾患治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他）
・世界の非アルコール性脂肪肝疾患治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他）
・北米の非アルコール性脂肪肝疾患治療薬市場分析：米国、カナダ
・ヨーロッパの非アルコール性脂肪肝疾患治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの非アルコール性脂肪肝疾患治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の非アルコール性脂肪肝疾患治療薬市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの非アルコール性脂肪肝疾患治療薬市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Merck、Pfizer、Novartis、GlaxoSmithKline、Allergan
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver cell damage.

Market Analysis and Insights: Global Nonalcoholic Fatty Liver Disease Therapeutics Market
The global Nonalcoholic Fatty Liver Disease Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Nonalcoholic Fatty Liver Disease Therapeutics Scope and Market Size
Nonalcoholic Fatty Liver Disease Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Nonalcoholic Fatty Liver Disease Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Merck
Pfizer
Novartis
GlaxoSmithKline
Allergan
…

Market segment by Type, the product can be split into
Oral
Parenteral
Market segment by Application, split into
Hospital
Clinic
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Nonalcoholic Fatty Liver Disease Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Oral
1.4.3 Parenteral
1.5 Market by Application
1.5.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Perspective (2015-2026)
2.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Growth Trends by Regions
2.2.1 Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Nonalcoholic Fatty Liver Disease Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Nonalcoholic Fatty Liver Disease Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Nonalcoholic Fatty Liver Disease Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Market Size
3.1.1 Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Concentration Ratio
3.2.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Nonalcoholic Fatty Liver Disease Therapeutics Revenue in 2019
3.3 Nonalcoholic Fatty Liver Disease Therapeutics Key Players Head office and Area Served
3.4 Key Players Nonalcoholic Fatty Liver Disease Therapeutics Product Solution and Service
3.5 Date of Enter into Nonalcoholic Fatty Liver Disease Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)
5.2 Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2015-2020)
6.2 Nonalcoholic Fatty Liver Disease Therapeutics Key Players in North America (2019-2020)
6.3 North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020)
6.4 North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2015-2020)
7.2 Nonalcoholic Fatty Liver Disease Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020)
7.4 Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2015-2020)
8.2 Nonalcoholic Fatty Liver Disease Therapeutics Key Players in China (2019-2020)
8.3 China Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020)
8.4 China Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2015-2020)
9.2 Nonalcoholic Fatty Liver Disease Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020)
9.4 Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2015-2020)
10.2 Nonalcoholic Fatty Liver Disease Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2015-2020)
11.2 Nonalcoholic Fatty Liver Disease Therapeutics Key Players in India (2019-2020)
11.3 India Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020)
11.4 India Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Size (2015-2020)
12.2 Nonalcoholic Fatty Liver Disease Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview
13.1.3 Merck Nonalcoholic Fatty Liver Disease Therapeutics Introduction
13.1.4 Merck Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Pfizer
13.2.1 Pfizer Company Details
13.2.2 Pfizer Business Overview
13.2.3 Pfizer Nonalcoholic Fatty Liver Disease Therapeutics Introduction
13.2.4 Pfizer Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020)
13.2.5 Pfizer Recent Development
13.3 Novartis
13.3.1 Novartis Company Details
13.3.2 Novartis Business Overview
13.3.3 Novartis Nonalcoholic Fatty Liver Disease Therapeutics Introduction
13.3.4 Novartis Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020)
13.3.5 Novartis Recent Development
13.4 GlaxoSmithKline
13.4.1 GlaxoSmithKline Company Details
13.4.2 GlaxoSmithKline Business Overview
13.4.3 GlaxoSmithKline Nonalcoholic Fatty Liver Disease Therapeutics Introduction
13.4.4 GlaxoSmithKline Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020)
13.4.5 GlaxoSmithKline Recent Development
13.5 Allergan
13.5.1 Allergan Company Details
13.5.2 Allergan Business Overview
13.5.3 Allergan Nonalcoholic Fatty Liver Disease Therapeutics Introduction
13.5.4 Allergan Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020)
13.5.5 Allergan Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Nonalcoholic Fatty Liver Disease Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Nonalcoholic Fatty Liver Disease Therapeutics Revenue
Table 3. Ranking of Global Top Nonalcoholic Fatty Liver Disease Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Oral
Table 6. Key Players of Parenteral
Table 7. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Regions (2015-2020)
Table 11. Global Nonalcoholic Fatty Liver Disease Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Nonalcoholic Fatty Liver Disease Therapeutics Market Growth Strategy
Table 17. Main Points Interviewed from Key Nonalcoholic Fatty Liver Disease Therapeutics Players
Table 18. Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 19. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Players (2015-2020)
Table 20. Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Fatty Liver Disease Therapeutics as of 2019)
Table 21. Global Nonalcoholic Fatty Liver Disease Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Nonalcoholic Fatty Liver Disease Therapeutics Product Solution and Service
Table 24. Date of Enter into Nonalcoholic Fatty Liver Disease Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 27. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Share by Type (2015-2020)
Table 28. Global Nonalcoholic Fatty Liver Disease Therapeutics Revenue Market Share by Type (2021-2026)
Table 29. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Share by Application (2015-2020)
Table 30. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 31. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size Share by Application (2021-2026)
Table 32. North America Key Players Nonalcoholic Fatty Liver Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Nonalcoholic Fatty Liver Disease Therapeutics Market Share (2019-2020)
Table 34. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 35. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type (2015-2020)
Table 36. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 37. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application (2015-2020)
Table 38. Europe Key Players Nonalcoholic Fatty Liver Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Nonalcoholic Fatty Liver Disease Therapeutics Market Share (2019-2020)
Table 40. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type (2015-2020)
Table 42. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application (2015-2020)
Table 44. China Key Players Nonalcoholic Fatty Liver Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 45. China Key Players Nonalcoholic Fatty Liver Disease Therapeutics Market Share (2019-2020)
Table 46. China Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 47. China Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type (2015-2020)
Table 48. China Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 49. China Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application (2015-2020)
Table 50. Japan Key Players Nonalcoholic Fatty Liver Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Nonalcoholic Fatty Liver Disease Therapeutics Market Share (2019-2020)
Table 52. Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type (2015-2020)
Table 54. Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Nonalcoholic Fatty Liver Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Nonalcoholic Fatty Liver Disease Therapeutics Market Share (2019-2020)
Table 58. Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type (2015-2020)
Table 60. Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application (2015-2020)
Table 62. India Key Players Nonalcoholic Fatty Liver Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 63. India Key Players Nonalcoholic Fatty Liver Disease Therapeutics Market Share (2019-2020)
Table 64. India Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 65. India Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type (2015-2020)
Table 66. India Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 67. India Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Nonalcoholic Fatty Liver Disease Therapeutics Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Nonalcoholic Fatty Liver Disease Therapeutics Market Share (2019-2020)
Table 70. Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type (2015-2020)
Table 72. Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application (2015-2020)
Table 74. Merck Company Details
Table 75. Merck Business Overview
Table 76. Merck Product
Table 77. Merck Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020) (Million US$)
Table 78. Merck Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Product
Table 82. Pfizer Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020) (Million US$)
Table 83. Pfizer Recent Development
Table 84. Novartis Company Details
Table 85. Novartis Business Overview
Table 86. Novartis Product
Table 87. Novartis Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020) (Million US$)
Table 88. Novartis Recent Development
Table 89. GlaxoSmithKline Company Details
Table 90. GlaxoSmithKline Business Overview
Table 91. GlaxoSmithKline Product
Table 92. GlaxoSmithKline Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020) (Million US$)
Table 93. GlaxoSmithKline Recent Development
Table 94. Allergan Company Details
Table 95. Allergan Business Overview
Table 96. Allergan Product
Table 97. Allergan Revenue in Nonalcoholic Fatty Liver Disease Therapeutics Business (2015-2020) (Million US$)
Table 98. Allergan Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Oral Features
Figure 3. Parenteral Features
Figure 4. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Application: 2020 VS 2026
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. Nonalcoholic Fatty Liver Disease Therapeutics Report Years Considered
Figure 9. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Regions: 2020 VS 2026
Figure 11. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Nonalcoholic Fatty Liver Disease Therapeutics Market Share by Players in 2019
Figure 14. Global Top Nonalcoholic Fatty Liver Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nonalcoholic Fatty Liver Disease Therapeutics as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Nonalcoholic Fatty Liver Disease Therapeutics Revenue in 2019
Figure 16. North America Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Nonalcoholic Fatty Liver Disease Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

以下、関連資料のご紹介
  • 非アルコール性脂肪性肝疾患治療の世界市場（～2026年）
    Global Non Alcoholic Fatty Liver Disease Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY03992 2020年11月20日 97Pages
    当調査資料は非アルコール性脂肪性肝疾患治療のグローバル市場について調査・分析したレポートです。種類別（酸化防止剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体作動薬、その他）市場規模、用途別（病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他）市場規模、地域別（北米、米国、カナダ...
  • 脂肪肝治療の世界市場（～2026年）
    Global Fatty Liver Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY11923 2020年11月25日 93Pages
    当調査資料は脂肪肝治療のグローバル市場について調査・分析したレポートです。種類別（チアゾリジンジオン、ビタミンE、メトホルミンスタチン、多価不飽和脂肪酸、アンジオテンシン受容体遮断薬、ペントキシフィリン）市場規模、用途別（病院・クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ド...
  • 非アルコール性脂肪性肝炎（NASH）の世界市場（～2026年）
    Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2020-2026
    MRC2-11QY03996 2020年11月20日 95Pages
    当調査資料は非アルコール性脂肪性肝炎（NASH）のグローバル市場について調査・分析したレポートです。種類別（オベチコール酸（OCA）、セロンセルチブ、エムリカサン、GR-MD-02、IMM-124E）市場規模、用途別（病院薬局、オンラインプロバイダー、小売薬局）市場規模、地域別（北米、米国、カナダ、...
  • 肝疾患治療の世界市場（～2026年）
    Global Liver Disease Treatment Market Size, Status and Forecast 2020-2026
    MRC2-11QY12531 2020年11月25日 94Pages
    当調査資料は肝疾患治療のグローバル市場について調査・分析したレポートです。種類別（肝臓有毒傷害、感染性病原体・寄生虫、免疫障害、腫瘍、遺伝性肝疾患）市場規模、用途別（病院、専門クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中...
  • 遊離脂肪酸受容体4の世界市場（～2026年）
    Global Free Fatty Acid Receptor 4 Market Insights and Forecast to 2026
    MRC2-11QY06507 2020年11月20日 113Pages
    当調査資料は遊離脂肪酸受容体4のグローバル市場について調査・分析したレポートです。種類別（CB-001、GSK-137647A、SC-410、その他）市場規模、用途別（非アルコール性脂肪性肝疾患、2型糖尿病、代謝性疾患、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギ...
  • アルツハイマー病治療薬の世界市場（～2026年）
    Global Alzheimers Disease Therapeutics Market Size, Status and Forecast 2020-2026
    MRC2-11QY13670 2020年11月30日 94Pages
    当調査資料はアルツハイマー病治療薬のグローバル市場について調査・分析したレポートです。種類別（バイオマーカー、コリンエステラーゼ阻害剤、NMDA受容体拮抗薬）市場規模、用途別（病院、診療所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、...
  • 胃食道逆流症（GERD）治療薬の世界市場（～2026年）
    Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Size, Status and Forecast 2020-2026
    MRC2-11QY12006 2020年11月25日 98Pages
    当調査資料は胃食道逆流症（GERD）治療薬のグローバル市場について調査・分析したレポートです。種類別（制酸剤、運動促進薬、H2受容体遮断薬、プロトンポンプ阻害薬（PPI））市場規模、用途別（胸やけ、酸逆流症）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシ...
  • 慢性肝疾患治療薬の世界市場（～2026年）
    Global Chronic Liver Diseases Therapeutics Market Size, Status and Forecast 2020-2026
    MRC2-11QY11365 2020年11月25日 131Pages
    当調査資料は慢性肝疾患治療薬のグローバル市場について調査・分析したレポートです。種類別（化学療法薬、標的療法、ワクチン、抗ウイルス薬、免疫グロブリン、コルチコステロイド、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、...
  • 獣医感染症治療薬の世界市場（～2026年）
    Global Veterinary Infectious Disease Therapeutics Market Size, Status and Forecast 2020-2026
    MRC2-11QY05015 2020年11月20日 92Pages
    当調査資料は獣医感染症治療薬のグローバル市場について調査・分析したレポートです。種類別（抗生物質、抗ウイルス剤、抗真菌剤、殺菌剤、駆虫剤）市場規模、用途別（獣医病院、獣医クリニック、獣医薬局、研究所）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジ...
  • フォンウィルブランド病（VWD）治療薬の世界市場（～2026年）
    Global Von Willebrand Disease (VWD) Therapeutics Market Size, Status and Forecast 2020-2026
    MRC2-11QY05054 2020年11月20日 92Pages
    当調査資料はフォンウィルブランド病（VWD）治療薬のグローバル市場について調査・分析したレポートです。種類別（デスモプレシン、血栓安定化薬、線維素溶解阻害剤、補充療法、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イ...
  • 非アルコール性脂肪性肝疾患治療の世界市場（～2026年）非アルコール性脂肪性肝疾患治療の世界市場（～2026年） Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-…
  • 脂肪肝治療の世界市場（～2026年）脂肪肝治療の世界市場（～2026年） Fatty liver disease is one of the most common liver dysfunction where the triglyceride fat accumulates in liver cells. The major risks associated with fatty liver disease are alcoholic cirrhosis, cardiovascular disorder, metabolic syndrome and biliary cirrhosis among others. Market Analysis and Insi…
  • 非アルコール性脂肪性肝炎（NASH）の世界市場（～2026年）非アルコール性脂肪性肝炎（NASH）の世界市場（～2026年） Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major fa…
  • 肝疾患治療の世界市場（～2026年）肝疾患治療の世界市場（～2026年） Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. Market Analysis and Insights: Global Liver Disease Treatment Market T…
  • 遊離脂肪酸受容体4の世界市場（～2026年）遊離脂肪酸受容体4の世界市場（～2026年） Market Analysis and Insights: Global Free Fatty Acid Receptor 4 Market The global Free Fatty Acid Receptor 4 market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Free Fatty Acid Receptor 4 Scope and Market Size Free Fatty A…